Nitya R Ramreddy, MD
Rheumatology · Glen Ridge
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Mpv New Jersey MD Services PC · 146 clinicians in this group
Hospitals listed: Hackensack Meridian Mountainside Medical. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ramreddy’s office at (973) 748-9246 to ask if they take your plan before you enroll.
California Medical Board record
Licence A185287 · Delinquent
Licence status: Delinquent · since 2023 · expires 2025-04-30 · Ntr University of Health Sciences, Mediciti Institute of Medical Sciences.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- New Jersey 25MA12498700Medical Doctor · since 2024 · expires 2027-06-30Matched by name, not licence number; check the name before relying on it.ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Hackensack Meridian Mountainside MedicalMontclair, NJAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Ardent Health Services, which runs 31 hospitals in 5 statesPatients rate it 2 of 5 · 62% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for Hackensack Meridian Mountainside Medical
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.1 (0.11 to 2.09) · 849 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.94 (0.58 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 146.22 (92.02 to 200.42) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 117 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 378 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.3 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 2,442 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.11 to 0.53) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.03 to 0.42) · 5,439 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.07 to 6.5) · 814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.3) · 203 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.96 (0.37 to 3.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.2 (0 to 16.12) · 210 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.71 (0.59 to 8.83) · 197 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.02 (0.52 to 3.53) · 222 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.26) · 4,306 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5 · 104 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.045 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.136 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.486 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 119 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 517 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -47.5 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.9 · 415 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 10.8 · 468 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 607 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.1 to 7.3) · 43 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.5 (8.8 to 17.1) · 43 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12 (9.3 to 15.6) · 1,196 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 361 cases | No different | Jan 2024 – Dec 2024 |
What patients said (683 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 80% |
Original Medicare doctor bills
$55,706
Medicare paid this office $55,706 for 198 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 97 | $18,441 | $190 |
| Return visit (30+ min) | 96 | $17,741 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,154 | $154 |
| Long return visit (40+ min) | 21 | $4,041 | $162 |
| New patient visit (45+ min) | 28 | $3,645 | $130 |
See all 7 services
| New patient visit (60+ min) | 97 | $18,441 | $190 |
| Return visit (30+ min) | 96 | $17,741 | $117 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,154 | $154 |
| Long return visit (40+ min) | 21 | $4,041 | $162 |
| New patient visit (45+ min) | 28 | $3,645 | $130 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 103 | $2,812 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,421 | $105 |
Who their Medicare patients are
198 Original Medicare patients in 2024. Average age 71 · Women 65% · Also on Medicaid 27% · Health risk score 1.75. Above the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 75% · Chronic kidney disease 35% · Coronary heart disease 32% · Diabetes 27% · Depression 25% · Heart failure 23% · COPD 19% · Atrial fibrillation 18% · Cancer 17% · Stroke 14% · Dementia 7%.
The office billed $248,081, Medicare allowed $73,401 and paid $55,706; for 593 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 198 | 593 | 71 | 1.75 | $248,081 | $55,706 |
| 2023 | 122 | 343 | 73 | 1.27 | $93,616 | $22,919 |
| 2022 | 91 | 391 | 75 | 1.25 | $71,215 | $23,732 |
| 2020 | 52 | 82 | 65 | 2.88 | $28,989 | $6,667 |
| 2019 | 31 | 49 | 67 | 1.87 | $23,709 | $5,136 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 60 | $7,809 | $96 |
| New patient visit (45+ min) | 44 | $5,501 | $125 |
| New patient visit (60+ min) | 15 | $3,105 | $207 |
| Short return visit (20+ min) | 20 | $1,260 | $60 |
| Telehealth originating site facility fee | 27 | $651 | $22 |
2022: 5 services
| Return visit (30+ min) | 57 | $8,041 | $109 |
| Short return visit (20+ min) | 35 | $3,081 | $77 |
| New patient visit (45+ min) | 21 | $2,935 | $140 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 12 | $2,747 | None |
| Aspiration and/or injection of fluid from large joint | 12 | $2,131 | $76 |
Medicaid work
$1,741 in 2023
Medicaid paid $1,741 for 43 billed services this clinician did in 2023, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 43 | $1,741 |
| 2023 | 43 | 1 | 15 | $1,741 |
Drugs they prescribed that Part D paid
$394,911
Pharmacies billed $394,911 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 355) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
312 generic and 43 brand-name prescriptions · $394,911 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tavneos | 17 | $252,380 | $14,846 |
| Simponi | 11 | $68,722 | $6,247 |
| Hydroxychloroquine Sulfate | 50 | $1,711 | $34 |
| Prednisone | 111 | $1,217 | $11 |
| Methotrexate | 41 | $942 | $23 |
See all 9 drugs
| Tavneos | 17 | $252,380 | $14,846 |
| Simponi | 11 | $68,722 | $6,247 |
| Hydroxychloroquine Sulfate | 50 | $1,711 | $34 |
| Prednisone | 111 | $1,217 | $11 |
| Methotrexate | 41 | $942 | $23 |
| Mycophenolate Mofetil | 15 | $753 | $50 |
| Colchicine | 19 | $689 | $36 |
| Allopurinol | 19 | $163 | $9 |
| Pantoprazole | 13 | $46 | $4 |
Year by year
| 2024 | 355 | 77 | 0% (0) | 12% | $394,911 |
| 2023 | 435 | 140 | 12% (53) | 4% | $37,809 |
| 2022 | 579 | 160 | 24% (141) | None | $120,476 |
| 2021 | 323 | 126 | 20% (64) | 3% | $30,875 |
| 2020 | 234 | 60 | 0% (0) | 21% | $144,598 |
| 2019 | 129 | 37 | 0% (0) | 18% | $65,449 |
| 2018 | 105 | 16 | 0% (0) | 28% | $52,893 |
| 2017 | 24 | None | 0% (0) | None | $1,512 |
| 2015 | 71 | 31 | None | None | $2,794 |
| 2014 | 85 | 23 | 0% (0) | None | $4,213 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Hydroxychloroquine Sulfate | 92 | $5,682 | $62 |
| Methotrexate | 65 | $2,962 | $46 |
| Prednisone | 52 | $535 | $10 |
| Oxycodone-Acetaminophen | 15 | $471 | $31 |
| Gabapentin | 31 | $358 | $12 |
| Duloxetine | 14 | $302 | $22 |
| Vitamin D2 | 28 | $264 | $9 |
| Colchicine | 12 | $264 | $22 |
| Tramadol | 28 | $124 | $4 |
2022: 10 drugs
| Forteo | 16 | $67,699 | $4,231 |
| Hydroxychloroquine Sulfate | 78 | $7,337 | $94 |
| Oxycodone-Acetaminophen | 54 | $2,366 | $44 |
| Methotrexate | 69 | $1,401 | $20 |
| Prednisone | 53 | $719 | $14 |
| Hydrocodone-Acetaminophen | 30 | $554 | $18 |
| Gabapentin | 37 | $398 | $11 |
| Vitamin D2 | 52 | $352 | $7 |
| Tramadol | 42 | $164 | $4 |
| Folic Acid | 16 | $82 | $5 |
2021: 10 drugs
| Hydroxychloroquine Sulfate | 42 | $2,997 | $71 |
| Oxycodone-Acetaminophen | 33 | $1,458 | $44 |
| Methotrexate | 37 | $1,351 | $37 |
| Diclofenac | 12 | $762 | $64 |
| Prednisone | 35 | $335 | $10 |
| Hydrocodone-Acetaminophen | 13 | $236 | $18 |
| Gabapentin | 18 | $151 | $8 |
| Methylprednisolone | 11 | $128 | $12 |
| Tramadol | 15 | $98 | $7 |
| Vitamin D2 | 12 | $80 | $7 |
2020: 5 drugs
| Diclofenac | 38 | $2,356 | $62 |
| Hydroxychloroquine Sulfate | 38 | $2,254 | $59 |
| Leflunomide | 12 | $1,508 | $126 |
| Prednisone | 49 | $604 | $12 |
| Methotrexate | 12 | $554 | $46 |
2019: 3 drugs
| Hydroxychloroquine Sulfate | 29 | $3,039 | $105 |
| Diclofenac | 11 | $793 | $72 |
| Prednisone | 19 | $209 | $11 |
2018: 2 drugs
| Voltaren | 14 | $1,343 | $96 |
| Hydroxychloroquine Sulfate | 19 | $1,117 | $59 |
Money from drug and device companies
$1,067 in 2025
| 2025 | 23 | 54 | None | $1,067 |
| 2024 | 1 | 1 | None | $27 |
| 2023 | 13 | 62 | None | $1,677 |
| 2022 | 10 | 79 | None | $1,373 |
| 2021 | 10 | 43 | None | $892 |
| 2020 | 1 | 1 | None | $23 |
| 2019 | 3 | 9 | None | $419 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Uplizna | $136 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $122 | 1 payment
|
| Ucb | Bimzelx | $83 | 5 payments
|
| Janssen Biotech | Tremfya | $82 | 5 payments
|
| Xeris Pharmaceuticals | Recorlev | $82 | 4 payments
|
| Abbvie | Rinvoq | $66 | 4 payments
|
See all 54 published payments
| Amgen | Meals · 2025-12-16 | Tavneos | $6 |
| Amgen | Meals · 2025-12-11 | Krystexxa | $3 |
| Abbvie | Meals · 2025-12-08 | Rinvoq | $18 |
| Ucb | Meals · 2025-12-05 | Bimzelx | $19 |
| Kyowa Kirin | Meals · 2025-12-04 | Crysvita | $20 |
| Alvogen | Meals · 2025-12-02 | Teriparatide | $21 |
| Janssen Biotech | Meals · 2025-11-25 | Tremfya | $17 |
| Amgen | Meals · 2025-11-20 | Tavneos | $18 |
| Amgen | Meals · 2025-10-29 | Krystexxa | $14 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-28 | Kerendia | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Tezspire | $122 |
| Sequel Med Tech | Meals · 2025-10-22 | Twiist | $23 |
| Ucb | Meals · 2025-10-17 | Bimzelx | $18 |
| Amgen | Meals · 2025-10-17 | Evenity | $17 |
| Amgen | Meals · 2025-10-08 | Uplizna | $19 |
| Alexion Pharmaceuticals | Meals · 2025-10-07 | Strensiq | $19 |
| Xeris Pharmaceuticals | Meals · 2025-10-06 | Recorlev | $21 |
| Alvogen | Meals · 2025-10-03 | Teriparatide | $17 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-29 | Orencia | $16 |
| Verona Pharma | Meals · 2025-09-29 | Ohtuvayre | $19 |
| Janssen Biotech | Meals · 2025-09-26 | Tremfya | $16 |
| Corcept Therapeutics | Meals · 2025-09-15 | Korlym | $20 |
| Averitas Pharma | Meals · 2025-09-13 | Qutenza | $16 |
| Ucb | Meals · 2025-09-11 | Bimzelx | $16 |
| Aurinia Pharma U.S. | Meals · 2025-09-10 | Lupkynis | $19 |
| Xeris Pharmaceuticals | Meals · 2025-09-09 | Recorlev | $22 |
| Amgen | Meals · 2025-09-04 | Tavneos | $16 |
| Abbvie | Meals · 2025-09-03 | Rinvoq | $17 |
| Electromed | Meals · 2025-09-02 | Smartvest | $15 |
| Verona Pharma | Meals · 2025-08-12 | Ohtuvayre | $18 |
| Radius Health | Meals · 2025-08-06 | Tymlos | $19 |
| Ucb | Meals · 2025-08-05 | Bimzelx | $15 |
| Ucb | Meals · 2025-08-01 | Bimzelx | $15 |
| Aurinia Pharma U.S. | Meals · 2025-07-31 | Lupkynis | $20 |
| Xeris Pharmaceuticals | Meals · 2025-07-31 | Recorlev | $20 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-21 | Entyvio | $16 |
| Janssen Biotech | Meals · 2025-07-18 | Tremfya | $18 |
| Abbvie | Meals · 2025-07-16 | Rinvoq | $14 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-15 | None | $14 |
| Alexion Pharmaceuticals | Meals · 2025-07-10 | Strensiq | $14 |
| Amgen | Meals · 2025-07-08 | Uplizna | $10 |
| Janssen Biotech | Meals · 2025-06-24 | Tremfya | $16 |
| Exact Sciences | Meals · 2025-06-19 | Cologuard Collection Kit | $32 |
| Amgen | Meals · 2025-06-10 | Krystexxa | $16 |
| Lilly USA | Meals · 2025-06-02 | Omvoh | $18 |
| Lilly USA | Meals · 2025-05-28 | Zepbound | $16 |
| Xeris Pharmaceuticals | Meals · 2025-05-27 | Recorlev | $20 |
| Abbvie | Meals · 2025-05-21 | Rinvoq | $17 |
| Janssen Biotech | Meals · 2025-05-15 | Tremfya | $15 |
| Insulet | Meals · 2025-05-15 | Omnipod | $27 |
| Corcept Therapeutics | Meals · 2025-05-08 | Korlym | $32 |
| Amgen | Meals · 2025-05-06 | Uplizna | $15 |
| Lilly USA | Meals · 2025-05-05 | Omvoh | $19 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-01 | Entyvio | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $27
| Janssen Biotech | Tremfya | $27 | 1 payment
|
2023: $1,677
| Janssen Biotech | Tremfya | $360 | 15 payments
|
| Abbvie | Rinvoq | $294 | 7 payments
|
| Ucb | Cimzia | $200 | 4 payments
|
| Amgen | Enbrel | $163 | 6 payments
|
| Aurinia Pharma U.S. | Lupkynis | $105 | 4 payments
|
| GlaxoSmithKline | Benlysta | $103 | 5 payments
|
| Horizon Therapeutics plc | Krystexxa | $92 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $90 | 5 payments
|
| Lilly USA | Taltz | $79 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $73 | 3 payments
|
| Alvogen | Teriparatide | $48 | 2 payments
|
| Radius Health | Tymlos | $45 | 2 payments
|
| Pfizer | Xeljanz | $24 | 1 payment
|
2022: $1,373
| Janssen Biotech | Tremfya | $355 | 39 payments
|
| Abbvie | Rinvoq | $264 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $218 | 10 payments
|
| Radius Health | Tymlos | $156 | 9 payments
|
| GlaxoSmithKline | Benlysta | $115 | 6 payments
|
| Aurinia Pharma U.S. | Lupkynis | $104 | 5 payments
|
| Amgen | Enbrel | $61 | 3 payments
|
| Alvogen | Teriparatide | $51 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $29 | 2 payments
|
| DePuy Synthes Sales | Orthovisc | $20 | 1 payment
|
2021: $892
| E.R. Squibb & Sons L.L.C. | Orencia | $220 | 7 payments
|
| Janssen Biotech | Tremfya | $211 | 14 payments
|
| Radius Health | Tymlos | $111 | 5 payments
|
| AbbVie | Rinvoq | $91 | 4 payments
|
| Aurinia Pharma U.S. | Lupkynis | $64 | 3 payments
|
| Horizon Therapeutics plc | Krystexxa | $57 | 3 payments
|
| Amgen | Evenity | $51 | 3 payments
|
| GlaxoSmithKline | Benlysta | $40 | 2 payments
|
| Ucb | Cimzia | $28 | 1 payment
|
| Organon | Renflexis | $18 | 1 payment
|
2020: $23
| Lilly USA | Taltz | $23 | 1 payment
|
2019: $419
| GlaxoSmithKline | Benlysta | $216 | 3 payments
|
| Janssen Scientific Affairs | Stelara | $172 | 3 payments
|
| Janssen Biotech | Simponi Aria | $30 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962813899
- Licence
- CA A185287California A185287: Delinquent · expires 2025-04-30New Jersey 25MA12498700: Active
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 311 Bay Ave Ste 300a, Glen Ridge, NJ, 07028
- NPI first listed
- 2014-05-13
- NPI last updated
- 2025-06-16
- NPI record certified
- 2025-06-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1500 S Fairfield Ave, Chicago, IL, 60608 · 20880 W Dixie Hwy Ste 101, Miami, FL, 33180 · 8932 Sw 97th Ave, Miami, FL, 33176 · 300 Pasteur Dr, Stanford, CA, 94305